Skip to main content

Table 1 General characteristics of patients with HIV and concomitant CRC according to antiviral regimens (n = 66)

From: Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer

Demographic characteristics

DTG/3TC/TDF (group I) n = 20

DTG/ABT (group II) n = 24

BIC/TAF/FTC (group III) n = 22

Sex

 Male

13

18

8

 Female

7

6

14

 Age (yeras)

61.5 (44–74)

60.04 (45–85)

54.27 (33–74)

 BMI (kg/m2)

23.37 (18.37–28.23)

22.74 (17.97–26.81)

23.73 (18.03–25.30)

TNM stage

 II

14

10

18

 III

6

14

4

Differentiation

 Well differentiated

0

3

2

 Moderately differentiated

15

14

16

 Poorly differentiated

5

7

4

 Baseline CD4 count (cells/ul)

368.35 (195–980)

272.71 (83–757)

315.14 (85–980)

 CD4/CD8 ratio

0.91 (0.19–2.87)

0.75 (0.14–2.86)

0.60 (0.08–1.68)

Type of cancer

 Rectal

6

11

4

 Colon

14

13

18

 Comorbidities

   

 Hypertension

2

1

2

 Diabetes mellitus

4

1

3

 HBV

1

1

1

 HCV

1

2

0

Type of surgery

 Right hemicolectomy

3

9

6

 Left hemicolectomy

5

1

4

 Sigmoidectomy

6

3

8

 Low anterior resection

6

11

4

Baseline HIV viral load (copies/ml)

  ≤ 20

18

19

17

 20–1000

1

1

2

  > 1000

1

4

3

Chemotherapy regimen

 CapeOX

16

19

22

 mFolfox6

4

5

0

 Untreated patients

1

4

3

 Pretreated patients

19

20

19

  1. CRC = Colorectal cancer
  2. DTG/3TC/TDF = dolutegravir/lamivudine/tenofovir
  3. DTG/ABT = dolutegravir/albuvirtide
  4. BIC/TAF/FTC = bictegravir/tenofovir alafenamide/emtricitabine
  5. BMI = Body Mass Index
  6. TNM stage was according to the AJCC 8th classification